Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
124I-F16SIP
- Development stage
- Unknown
- Lead developer
- Philogen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**124I-F16SIP** is an iodine-124-labeled human monoclonal antibody fragment (specifically, a small immunoprotein [SIP] or single-chain Fv antibody) that selectively targets the extra-domain A1 of **tenascin-C**, a protein highly expressed in the extracellular matrix of tumors and neovasculature. The drug is used for **PET imaging** (immunoPET) of cancers, including head and neck cancer and various solid tumors, by localizing specifically to tumors expressing tenascin-C. Its mechanism of action as an imaging agent stems from the emission of positrons by iodine-124, enabling visualization through PET scanning. It has shown good bioavailability, selective tumor targeting, and was well tolerated in clinical microdosing studies.
- Brand names
- Tenapet
- Other names
- Monoclonal antibody F16 I 124Iodine-124-labelled F-16 scFv antibodyIodine124-labelled F-16 scFv antibodyIodine 124-labelled F-16 scFv antibody
02
Targets
TNC-A1 (Tenascin-C fibronectin type III-A1 domain)
Beyond the preview
Go deeper on 124I-F16SIP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 124I-F16SIP.